How Medical Affairs Teams Are Affected By Cybersecurity And Data Privacy Issues

Data integrity is one of the most critical factors related to medical affairs and pharmaceutical development. However, the growth of medical affairs teams and their use of digital communication also creates risk, causing an increase in opportunities for data breaches or compliance issues—especially because of the relative newness of this field.

While the short-term effects of poor data integrity could cause the FDA to reject a study and prevent treatment from going to market, long-term data issues could affect the reputation of a company and create additional work for medical affairs teams.

“The FDA expects that all data submitted to the agency to obtain market approval is both reliable and accurate,” writes the team at professional services provider Astrix. “The FDA considers the integrity of data, from the moment it is generated, and extending through to the end of its life cycle, to be a critical component of ensuring that only high-quality and safe drugs are manufactured.”

To prevent these issues, review this collection of common problems facing medical affairs teams regarding cybersecurity, privacy, and compliance.